Fertility study of the new pyrazolo-pyrimidinone derivative DA-8159 for erectile dysfunction in rats

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 3, 2004, Pages 179-186

  Chung, Moon Koo ^a   Kim, Jong Choon ^b   Kim, Won Bae ^c   Kang, Kyung Koo ^c   Han, Sang Seop ^a  

^a Korea Institute of Toxicology   (South Korea)

^b Chonnam National University   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

Author keywords

5 2 propyloxy 5 (1 methyl 2 pyrrolidinylethylamidosulfonyl)phenyl 1 methyl 3 propyl 1,6 dihydro 7h pyrazolo (4,3 d)pyrimidine 7 one; CAS 268203 93 6; DA 8159, fertility study; Rat erectile dysfunction

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; PYRAZOLOPYRIMIDINE DERIVATIVE; SILDENAFIL; TADALAFIL; UDENAFIL; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; EMBRYO DEVELOPMENT; ERECTILE DYSFUNCTION; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; IMPOTENCE; MALE; MALE FERTILITY; MATING; NONHUMAN; QUALITY OF LIFE; RAT; TESTOSTERONE BLOOD LEVEL;

EID: 1642330261     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296956     Document Type: Article

References (25)

1. Korenmann, S. G., Clinical review 71: Advances in the understanding and management of erectile dysfunction. J. Clin. Endocrinol. Metab. 80, 1985 (1995)
2. Furlow, W. L., Prevalence of impotence in the United States. Medical Aspects of Human Sexuality 19, 13 (1985)
3. Wagener, G., Saenz de Tajada, I., Fortnightly review update on male erectile dysfunction. Br. J. Pharmacol. 22, 246 (1998)
4. Klotz, T., Sachse, R., Heidrich, A. et al., Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol. 19, 32 (2001)
5. Ueckert, S., Kuethe, A., Stiel, C. G. et al., Phosphodiesterase isozymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Urol. 19, 14 (2001)
6. Padma-Nathan, H., McMurray, J. G., Pullman, W. E. et al., On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int. J. Impot. Res. 13, 2 (2001)
7. Marmor, M. F., Kessler, R., Sildenafil (Viagra) and opthalmology. Surv. Ophthalmol. 44, 153 (1999)
8. Oh, T. H., Kang K. K., Ahn, B. O. et al., Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch. Pharm. Res. 23, 471 (2000)
9. Ahn, B. O., 4-Week repeated dose toxicity study of DA-8159 in rats, Dong-A Pharm. Co. Study No. 000001, pp. 1-195, data on file (2000)
10. Kim, J. C., Lim, K. H., Chung, M. K., Testicular cytotoxicity of DA-125, a new anthracycline ancticancer agent, in rats. Reprod. Toxicol. 13, 171 (1999)
11. Thompson, W. J., Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol. Ther. 51, 13 (1991)
12. Nicholson, C. D., Challiss, R. A., Shahid, M., Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12, 19 (1991)
13. Hall, I. P., Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br. J. Clin. Pharmacol. 35, 1 (1993)
14. Michaeli, T., Bloom, T. J., Martins, T. et al., Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase deficient Saccharomyces cerevisiae. J. Biol. Chem. 268, 12925 (1994)
15. Rulten, S. L., Dapling, J. L., Lanfa, S. C. et al., Isolation of human phosphodiesterase 5 cDNA and in situ analysis of its expression in human corpus cavernosum. J. Urol. 159, 92A (1998)
16. Goldstein, J., Lue, T. E, Padma-Nathan, H. et al., Oral sildenafil in the treatment of erectile dysfunction. N. Eng. J. Med. 338, 1397 (1998)
17. Kuethe, A., Maegert, H. J., Ueckert, S. et al., Gene expression of the phosphodiesterase 3A and 5A in human corpus cavernosum. Eur. Urol. 38, 108 (2000)
18. Zenick, H., Clegg, E. D., Assessment of male reproductive toxicity: A risk assessment approach, in: A. W. Hayes (ed.), Principles and methods of toxicology, pp. 275-309, Raven Press, New York (1989)
19. Thielemans, B. F. J., Spiessens, C., Hooghe, T. et al., Genetic abnormalities and male infertility. A comprehensive review. Eur. J. Obstet. Gynecol. Reprod. Biol. 81, 217 (1998)
20. Foley, G. L., Mechanisms of male reproductive pathology. Toxicol. Pathol. 29, 49 (2001)
21. Kidd, S. A., Eskenazi, B., Wyrobek, A. J., Effects of male age on semen quality and fertility: a review of the literature. Fertil. Steril. 75, 237 (2001)
22. Banik, U. K., Givner, M. L., Effects of a luteinizing hormone-releasing hormone analog on mating and fertility in rats. Fertil. Steril. 27, 1078 (1976)
23. Kendle, K. E., Paterson, J. R., Wilson, C. A., Effects of RMI 12936, a synthetic antiprogesteronal steroid, on the estrus cycle and ovulation in the rat. J. Reprod. Fertil. 53, 363 (1978)
24. LaPolt, P. S., Matt, D. W., Lu, J. K. H., Progesterone implants delay age-related declines in regular estrous cyclicity and the ovarian follicular reserve in long-evans rats. Biol. Reprod. 59, 197 (1998)
25. Review and evaluation of pharmacology and toxicology data of Viagra tablets (sildenafil citrate), Pfizer Pharm. Co., FDA CDER NDA No. 020895, pp. 87-101; data on file